drugset / Trial / NCT04165096
KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) in combination with boserolimab (MK-5890), MK-4830, MK-0482 in participants with advanced squamous or non-squamous NSCLC that have been previously treated with anti-PD-L1 therapy. This study is one of three pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).
Timeline
- Start
- 2020-01-21
- Primary completion
- 2025-04-30
- Completion
- 2025-05-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Boserolimab | Monoclonal antibody | — | Intravenous |
| Subject | MK-0482 | Unknown | — | Intravenous |
| Subject | MK-4830 | Unknown | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Acetaminophen | Small molecule | 500 mg | — |
| Background | Acetaminophen | Small molecule | 1000 mg | — |
| Background | Diphenhydramine | Unknown | 50 mg | — |